Ray Paranal, BA, (RaymondM_Paranal@dfci.harvard.edu) is involved in several compound screening efforts done in collaboration with the Nathanael Gray Lab, especially as they relate to the HER2 and EGFR mutant lung cancer.
Mierzhati Mushajiang, BS, (Mierzhati_Mushajiang@dfci.harvard.edu) aids in several efforts in the area of drug development and compound screens done in collaboration with the Nathanael Gray Lab, including the HER2 and EGFR targets. He is also involved in the generation of patient derived models.
Mika Lin, BA, (firstname.lastname@example.org) is involved in the processing of clinical specimens and establishment of patient-derived lung cancer cell lines. She also aids in the process of generating patient-derived xenograft (PDX) models.
Jiaqi Li, BA, (Jiaqi_Li@DFCI.HARVARD.EDU) assists in investigating the therapeutic effects of MAPK pathway inhibition in Ras mutant lung cancer cell lines.